Novel oral anticoagulants have fewer drug interactions than warfarin, making them suitable for elderly patients with atrial fibrillation, though caution is required regarding missed doses and varying indications for renal impairment.
Answers are grounded in this paper and cite their sources.
Supports NOAC preference in elderly AF with polypharmacy; leaves open adherence and renal dosing strategies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Shinichiro Uchiyama (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: